This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


Combination immunotherapy shows no additional benefit for most advanced cancers, finds meta-analysis

Credit: CC0 Public Domain

A combination immunotherapy treatment of nivolumab plus ipilimumab was associated with no improvement in survival for advanced cancers other than melanoma, when compared to nivolumab alone, according to a recent Northwestern Medicine meta-analysis published in JAMA Oncology.

"This revealed that in advanced cancers other than melanoma, the addition of ipilimumab to standard-dose nivolumab was not associated with a clinically meaningful improvement in overall survival or progression-free survival, while substantially increasing high-grade toxicities.

"Oncologists will hopefully consider these data carefully, along with the specific disease context, before prescribing or recommending addition of ipilimumab to standard-dose nivolumab in a non-melanoma advanced cancer," said Niraj Shenoy, MD, Ph.D., associate professor of Medicine in the Division of Hematology and Oncology and of Pathology and senior author of the study.

In the current analysis, investigators examined data from eight that covered more than 1,700 patients with different advanced cancers, including non–small cell lung cancer, , squamous cell lung cancer, pleural mesothelioma, urothelial carcinoma, esophagogastric carcinoma, sarcoma and glioblastoma multiforme.

Overall, the analysis revealed that treatment with nivolumab plus ipilimumab was not associated with improvement in overall or compared to nivolumab alone. The combination treatment was also associated with substantially higher toxicity compared to the monotherapy.

The findings suggest that nivolumab plus ipilimumab may be unnecessary for patients with other than melanoma, and that nivolumab monotherapy may provide similar clinical outcomes with reduced toxicity, according to the authors.

"For cancers in which nivolumab and ipilimumab combination therapy has been approved without comparison with nivolumab monotherapy, non-inferiority trials should be strongly considered," Shenoy said. "The meta-analysis serves as a sobering reminder to the oncology research community as well as regulatory bodies to refrain from assuming combinatorial superiority across cancers based on data in one cancer."

More information: Anthony V. Serritella et al, Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma, JAMA Oncology (2023). DOI: 10.1001/jamaoncol.2023.3295

Journal information: JAMA Oncology

Citation: Combination immunotherapy shows no additional benefit for most advanced cancers, finds meta-analysis (2023, September 22) retrieved 2 December 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Six-year follow-up data on survival, benefits for patients with metastatic NSCLC and nivolumab + ipilimumab treatment


Feedback to editors